Clinical Trial & License Agreement Update

AI SummaryClose X

Roquefort Therapeutics plc has amended its exclusive license agreement for AO-252 with Coiled Therapeutics, Inc. and A2A Pharmaceuticals, Inc., extending the long stop date to March 16, 2026, and increasing the upfront consideration to £31,875,000 in ordinary shares. The Phase I clinical trial for AO-252 has been expanded to include all solid tumours, with prostate cancer now prioritized as the primary indication following positive pre-clinical data and encouraging safety signals, including 100% complete response in VCaP xenografts and 90% tumor growth inhibition in 22Rv1 models. Deferred consideration shares are now tied to market capitalization targets of £60 million, £90 million, and £120 million, reflecting confidence in the program's progress and market potential, especially in light of recent acquisitions in the prostate cancer therapeutic space.

Disclaimer*

UK 100

Latest directors dealings